Pharmacotherapy of inflammatory bowel disease. Part 2. Metronidazole

M. S. Frank, Lawrence J. Brandt, L. H. Bernstein

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Studies have shown metronidazole to be useful in the treatment of colon Crohn's disease, especially for perineal complications. It appears to equal sulfasalazine in effectiveness and to offer hope to patients who fail to respond to that drug. However, exacerbation of perineal disease is to be expected on discontinuation of therapy. The only troublesome side effect is paresthesia, which apparently is dose-related and not progressive. Although no studies exist showing the drug to be mutagenic, teratogenic, or carcinogenic in humans, animal and laboratory tests raise concern of this possibility. For this reason, metronidazole therapy should be stopped in two to six months if ineffective and stopped periodically when disease is controlled to see if it can be discontinued.

Original languageEnglish (US)
Pages (from-to)155-160
Number of pages6
JournalPostgraduate Medicine
Volume74
Issue number6
StatePublished - 1983
Externally publishedYes

Fingerprint

Metronidazole
Inflammatory Bowel Diseases
Drug Therapy
Sulfasalazine
Paresthesia
Laboratory Animals
Crohn Disease
Pharmaceutical Preparations
Disease Progression
Colon
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Pharmacotherapy of inflammatory bowel disease. Part 2. Metronidazole. / Frank, M. S.; Brandt, Lawrence J.; Bernstein, L. H.

In: Postgraduate Medicine, Vol. 74, No. 6, 1983, p. 155-160.

Research output: Contribution to journalArticle

Frank, M. S. ; Brandt, Lawrence J. ; Bernstein, L. H. / Pharmacotherapy of inflammatory bowel disease. Part 2. Metronidazole. In: Postgraduate Medicine. 1983 ; Vol. 74, No. 6. pp. 155-160.
@article{dae93cb4018a4478952dbdcdd4fd596a,
title = "Pharmacotherapy of inflammatory bowel disease. Part 2. Metronidazole",
abstract = "Studies have shown metronidazole to be useful in the treatment of colon Crohn's disease, especially for perineal complications. It appears to equal sulfasalazine in effectiveness and to offer hope to patients who fail to respond to that drug. However, exacerbation of perineal disease is to be expected on discontinuation of therapy. The only troublesome side effect is paresthesia, which apparently is dose-related and not progressive. Although no studies exist showing the drug to be mutagenic, teratogenic, or carcinogenic in humans, animal and laboratory tests raise concern of this possibility. For this reason, metronidazole therapy should be stopped in two to six months if ineffective and stopped periodically when disease is controlled to see if it can be discontinued.",
author = "Frank, {M. S.} and Brandt, {Lawrence J.} and Bernstein, {L. H.}",
year = "1983",
language = "English (US)",
volume = "74",
pages = "155--160",
journal = "Postgraduate Medicine",
issn = "0032-5481",
publisher = "Medquest Communications LLC",
number = "6",

}

TY - JOUR

T1 - Pharmacotherapy of inflammatory bowel disease. Part 2. Metronidazole

AU - Frank, M. S.

AU - Brandt, Lawrence J.

AU - Bernstein, L. H.

PY - 1983

Y1 - 1983

N2 - Studies have shown metronidazole to be useful in the treatment of colon Crohn's disease, especially for perineal complications. It appears to equal sulfasalazine in effectiveness and to offer hope to patients who fail to respond to that drug. However, exacerbation of perineal disease is to be expected on discontinuation of therapy. The only troublesome side effect is paresthesia, which apparently is dose-related and not progressive. Although no studies exist showing the drug to be mutagenic, teratogenic, or carcinogenic in humans, animal and laboratory tests raise concern of this possibility. For this reason, metronidazole therapy should be stopped in two to six months if ineffective and stopped periodically when disease is controlled to see if it can be discontinued.

AB - Studies have shown metronidazole to be useful in the treatment of colon Crohn's disease, especially for perineal complications. It appears to equal sulfasalazine in effectiveness and to offer hope to patients who fail to respond to that drug. However, exacerbation of perineal disease is to be expected on discontinuation of therapy. The only troublesome side effect is paresthesia, which apparently is dose-related and not progressive. Although no studies exist showing the drug to be mutagenic, teratogenic, or carcinogenic in humans, animal and laboratory tests raise concern of this possibility. For this reason, metronidazole therapy should be stopped in two to six months if ineffective and stopped periodically when disease is controlled to see if it can be discontinued.

UR - http://www.scopus.com/inward/record.url?scp=0021070330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021070330&partnerID=8YFLogxK

M3 - Article

VL - 74

SP - 155

EP - 160

JO - Postgraduate Medicine

JF - Postgraduate Medicine

SN - 0032-5481

IS - 6

ER -